Key Takeaways
- The potential expansion of CGTs into prevalent conditions, including autoimmune disease, diabetes, and neurological disorders, could markedly change health outcomes on a broad scale.
- The migration of CAR-T therapies into community treatment sites is a promising development.
- Both community and academic delivery models play essential and complementary roles in expanding CGT access.